Nrf2 Activation in Chronic Kidney Disease: Promises and Pitfalls

Overview

Journal Antioxidants (Basel)

Date 2022 Jun 24

PMID 35740009

Authors

Ana Karina Aranda-Rivera

Alfredo Cruz-Gregorio

Jose Pedraza-Chaverri

Alexandra Scholze

Affiliations

Soon will be listed here.

Abstract

The nuclear factor erythroid 2-related factor 2 (Nrf2) protects the cell against oxidative damage. The Nrf2 system comprises a complex network that functions to ensure adequate responses to redox perturbations, but also metabolic demands and cellular stresses. It must be kept within a physiologic activity range. Oxidative stress and alterations in Nrf2-system activity are central for chronic-kidney-disease (CKD) progression and CKD-related morbidity. Activation of the Nrf2 system in CKD is in multiple ways related to inflammation, kidney fibrosis, and mitochondrial and metabolic effects. In human CKD, both endogenous Nrf2 activation and repression exist. The state of the Nrf2 system varies with the cause of kidney disease, comorbidities, stage of CKD, and severity of uremic toxin accumulation and inflammation. An earlier CKD stage, rapid progression of kidney disease, and inflammatory processes are associated with more robust Nrf2-system activation. Advanced CKD is associated with stronger Nrf2-system repression. Nrf2 activation is related to oxidative stress and moderate uremic toxin and nuclear factor kappa B (NF-κB) elevations. Nrf2 repression relates to high uremic toxin and NF-κB concentrations, and may be related to Kelch-like ECH-associated protein 1 (Keap1)-independent Nrf2 degradation. Furthermore, we review the effects of pharmacological Nrf2 activation by bardoxolone methyl, curcumin, and resveratrol in human CKD and outline strategies for how to adapt future Nrf2-targeted therapies to the requirements of patients with CKD.

Citing Articles

Combating chronic kidney disease-associated cachexia: A literature review of recent therapeutic approaches.

Rahbar Saadat Y, Abbasi A, Hejazian S, Hekmatshoar Y, Ardalan M, Farnood F BMC Nephrol. 2025; 26(1):133.

PMID: 40069669 PMC: 11895341. DOI: 10.1186/s12882-025-04057-8.

The Potential of Superoxide Dismutase-Rich as a Promoter of Cellular Health.

Cocksedge S, Mantecon L, Castano E, Infante C, Bailey S Int J Mol Sci. 2025; 26(4).

PMID: 40004157 PMC: 11855123. DOI: 10.3390/ijms26041693.

Serum adropin levels as a potential biomarker for predicting diabetic kidney disease progression.

Chen I, Lin C, Lin C, Chen S Front Endocrinol (Lausanne). 2025; 16:1511730.

PMID: 39991732 PMC: 11842233. DOI: 10.3389/fendo.2025.1511730.

Global research progress and trends in traditional Chinese medicine for chronic kidney disease since the 21st century: a bibliometric analysis.

Wang H, Wang J, Chen Y, Yang D, Xiong L Front Med (Lausanne). 2025; 11:1480832.

PMID: 39895816 PMC: 11782275. DOI: 10.3389/fmed.2024.1480832.

Future of Uremic Toxin Management.

Vanholder R, Snauwaert E, Verbeke F, Glorieux G Toxins (Basel). 2024; 16(11).

PMID: 39591217 PMC: 11598275. DOI: 10.3390/toxins16110463.

References

Rabbani N, Xue M, Weickert M, Thornalley P . Reversal of Insulin Resistance in Overweight and Obese Subjects by -Resveratrol and Hesperetin Combination-Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation. Nutrients. 2021; 13(7). PMC: 8308792. DOI: 10.3390/nu13072374. View

Rysz J, Franczyk B, Kujawski K, Sacewicz-Hofman I, Cialkowska-Rysz A, Gluba-Brzozka A . Are Nutraceuticals Beneficial in Chronic Kidney Disease?. Pharmaceutics. 2021; 13(2). PMC: 7915977. DOI: 10.3390/pharmaceutics13020231. View

Korn S, Wouters E, Vos N . Cytokine-induced activation of nuclear factor-kappa B is inhibited by hydrogen peroxide through oxidative inactivation of IkappaB kinase. J Biol Chem. 2001; 276(38):35693-700. DOI: 10.1074/jbc.M104321200. View

Li Z, Guo H, Li J, Ma T, Zhou S, Zhang Z . Sulforaphane prevents type 2 diabetes-induced nephropathy via AMPK-mediated activation of lipid metabolic pathways and Nrf2 antioxidative function. Clin Sci (Lond). 2020; 134(18):2469-2487. DOI: 10.1042/CS20191088. View

MacGarvey N, Suliman H, Bartz R, Fu P, Withers C, Welty-Wolf K . Activation of mitochondrial biogenesis by heme oxygenase-1-mediated NF-E2-related factor-2 induction rescues mice from lethal Staphylococcus aureus sepsis. Am J Respir Crit Care Med. 2012; 185(8):851-61. PMC: 3360573. DOI: 10.1164/rccm.201106-1152OC. View

Sies H, Jones D . Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020; 21(7):363-383. DOI: 10.1038/s41580-020-0230-3. View

Vanholder R, Nigam S, Burtey S, Glorieux G . What If Not All Metabolites from the Uremic Toxin Generating Pathways Are Toxic? A Hypothesis. Toxins (Basel). 2022; 14(3). PMC: 8953523. DOI: 10.3390/toxins14030221. View

Xu C, Shen G, Chen C, Gelinas C, Kong A . Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene. 2005; 24(28):4486-95. DOI: 10.1038/sj.onc.1208656. View

van Raaij S, Van Swelm R, Bouman K, Cliteur M, van den Heuvel M, Pertijs J . Tubular iron deposition and iron handling proteins in human healthy kidney and chronic kidney disease. Sci Rep. 2018; 8(1):9353. PMC: 6008459. DOI: 10.1038/s41598-018-27107-8. View

10.

Taguchi K, Fujikawa N, Komatsu M, Ishii T, Unno M, Akaike T . Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc Natl Acad Sci U S A. 2012; 109(34):13561-6. PMC: 3427110. DOI: 10.1073/pnas.1121572109. View

11.

Lewis J, Jadoul M, Block G, Chin M, Ferguson D, Goldsberry A . Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD. Clin Transl Sci. 2020; 14(1):299-309. PMC: 7877861. DOI: 10.1111/cts.12868. View

12.

Wu T, Zhao F, Gao B, Tan C, Yagishita N, Nakajima T . Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis. Genes Dev. 2014; 28(7):708-22. PMC: 4015486. DOI: 10.1101/gad.238246.114. View

13.

Pedruzzi L, Stockler-Pinto M, Leite Jr M, Mafra D . Nrf2-keap1 system versus NF-κB: the good and the evil in chronic kidney disease?. Biochimie. 2012; 94(12):2461-6. DOI: 10.1016/j.biochi.2012.07.015. View

14.

Leal V, Saldanha J, Stockler-Pinto M, Cardozo L, Santos F, Albuquerque A . NRF2 and NF-κB mRNA expression in chronic kidney disease: a focus on nondialysis patients. Int Urol Nephrol. 2015; 47(12):1985-91. DOI: 10.1007/s11255-015-1135-5. View

15.

Venditti P, Di Meo S . The Role of Reactive Oxygen Species in the Life Cycle of the Mitochondrion. Int J Mol Sci. 2020; 21(6). PMC: 7139706. DOI: 10.3390/ijms21062173. View

16.

Cuadrado A, Rojo A, Wells G, Hayes J, Cousin S, Rumsey W . Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019; 18(4):295-317. DOI: 10.1038/s41573-018-0008-x. View

17.

Kang J, Jeong M, Oh S, Jang E, Kim H, Hwang E . A FoxO1-dependent, but NRF2-independent induction of heme oxygenase-1 during muscle atrophy. FEBS Lett. 2013; 588(1):79-85. DOI: 10.1016/j.febslet.2013.11.009. View

18.

Tebay L, Robertson H, Durant S, Vitale S, Penning T, Dinkova-Kostova A . Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med. 2015; 88(Pt B):108-146. PMC: 4659505. DOI: 10.1016/j.freeradbiomed.2015.06.021. View

19.

Stockler-Pinto M, Soulage C, Borges N, Cardozo L, Dolenga C, Nakao L . From bench to the hemodialysis clinic: protein-bound uremic toxins modulate NF-κB/Nrf2 expression. Int Urol Nephrol. 2017; 50(2):347-354. DOI: 10.1007/s11255-017-1748-y. View

20.

Freigang S, Ampenberger F, Spohn G, Heer S, Shamshiev A, Kisielow J . Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol. 2011; 41(7):2040-51. DOI: 10.1002/eji.201041316. View